Method for treating prostatitis utilizing the pore-forming protein proaerolysin PRX302
The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins.
1. A method of treating prostatitis in a subject having prostatitis, said method comprising intraprostatically administering to said subject a therapeutically effective amount of PRX302,
wherein the PRX302 comprises an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4 and which maintains the ability to selectively target and kill normal prostate cells, wherein the PRX302 comprises a polyhistidine tag;
wherein said administering of the PRX302 results in a reduction in prostate volume.
2. The method of claim 1 , wherein administration results in at least a 10% reduction in prostate volume.
3. The method of claim 1 , wherein administration results in at least a 50% reduction in prostate volume.
4. The method of claim 1 , wherein the prostatitis is chronic prostatitis.
5. The method of claim 1 , further comprising administering an additional therapeutic agent for treating prostatitis.
6. The method of claim 5 , wherein the additional therapeutic agent comprises an α-1-adrenoreceptor antagonist, an antibiotic, an anti-inflammatory agent, a 5α reductase inhibitor, a phytotherapy, or any combination thereof.
7. The method of claim 1 , wherein the subject has one or more signs of prostatitis comprising a prostate volume of 30 to 100 mL, prostate specific antigen blood levels of 4-10 ng/mL, or a combination thereof.
8. The method of claim 1 , wherein the polyhistidine tag comprises six histidine residues at the C-terminal end of PRX302 (SEQ ID NO:4).
9. A method of treating prostatitis in a subject having prostatitis, said method comprising intraprostatically administering to said subject a therapeutically effective amount of PRX302,
wherein the PRX302 comprises an amino acid sequence having greater than 98% sequence identity to the amino acid sequence shown in SEQ ID NO:4 and which maintains the ability to selectively target and kill normal prostate cells, and a C-terminal polyhistidine tag that includes six histidine residues;
wherein said administering of the PRX302 results in a reduction in prostate volume.